Literature DB >> 25228780

A review of options for treating sialorrhea in amyotrophic lateral sclerosis.

Paolo Banfi1, Nicola Ticozzi2, Agata Lax3, Giulia Andrea Guidugli4, Antonello Nicolini5, Vincenzo Silani2.   

Abstract

Sialorrhea or drooling represents quite a common problem in patients with amyotrophic lateral sclerosis (ALS). In this review, we describe the possible treatments for this issue. Current medical management is not always effective: anticholinergic drugs (atropine, glycopyrrolate, amitriptyline, hyoscyamine, and transdermal scopolamine) are often used, but there is very little evidence of their effectiveness in patients with ALS. More invasive treatments, such as botulinum toxin injections and/or radiation therapy in the salivary glands, can be considered when anticholinergic drugs are not effective. In this review, we also explore the possible surgical options for treatment of sialorrhea. Although no specific studies have been conducted on patients with ALS, surgical therapies might represent a valid option for treatment of sialorrhea since there is no tachyphylaxis or need for repeated therapeutic sessions.
Copyright © 2015 by Daedalus Enterprises.

Entities:  

Keywords:  amyotrophic lateral sclerosis; aspiration pneumonia; botulinum toxin; drooling; quality of life; radiotherapy; salivary glands; sialorrhea; surgical intervention

Mesh:

Year:  2014        PMID: 25228780     DOI: 10.4187/respcare.02856

Source DB:  PubMed          Journal:  Respir Care        ISSN: 0020-1324            Impact factor:   2.258


  15 in total

1.  Radiotherapy treatment of the salivary glands, sialorrhea, and non-invasive mechanical ventilation in amyotrophic lateral sclerosis: what are we doing?

Authors:  Giancarlo Garuti; Jessica Mandrioli; Antonio M Esquinas
Journal:  J Neurol       Date:  2016-01-02       Impact factor: 4.849

Review 2.  Hypersalivation: update of the German S2k guideline (AWMF) in short form.

Authors:  Armin Steffen; Wolfgang Jost; Tobias Bäumer; Dirk Beutner; Sabine Degenkolb-Weyers; Martin Groß; Maria Grosheva; Samer Hakim; Kai G Kahl; Rainer Laskawi; Rebekka Lencer; Jan Löhler; Thekla Meyners; Saskia Rohrbach-Volland; Rainer Schönweiler; Sara-Christina Schröder; Sebastian Schröder; Heidrun Schröter-Morasch; Maria Schuster; Susanne Steinlechner; Roland Urban; Orlando Guntinas-Lichius
Journal:  J Neural Transm (Vienna)       Date:  2019-04-10       Impact factor: 3.575

Review 3.  Symptomatic treatments for amyotrophic lateral sclerosis/motor neuron disease.

Authors:  Louisa Ng; Fary Khan; Carolyn A Young; Mary Galea
Journal:  Cochrane Database Syst Rev       Date:  2017-01-10

4.  IncobotulinumtoxinA for hypersalivation in patients with amyotrophic lateral sclerosis: an open-label single-centre study.

Authors:  Lejla Paracka; Katja Kollewe; Martin Klietz; Susanne Petri; Dirk Dressler
Journal:  J Neural Transm (Vienna)       Date:  2019-07-17       Impact factor: 3.575

5.  Investigation of non-motor symptoms in patients with amyotrophic lateral sclerosis.

Authors:  Takehisa Hirayama; Mari Shibukawa; Masaru Yanagihashi; Hitoshi Warita; Naoki Atsuta; Koji Yamanaka; Osamu Kano
Journal:  Acta Neurol Belg       Date:  2022-08-20       Impact factor: 2.471

Review 6.  Comprehensive rehabilitative care across the spectrum of amyotrophic lateral sclerosis.

Authors:  Sabrina Paganoni; Chafic Karam; Nanette Joyce; Richard Bedlack; Gregory T Carter
Journal:  NeuroRehabilitation       Date:  2015       Impact factor: 2.138

7.  Long-term follow-up of ultrasound-guided botulinum toxin-A injections for sialorrhea in neurological dysphagia.

Authors:  Pierangelo Barbero; Marco Busso; Marco Tinivella; Carlo Alberto Artusi; Stefania De Mercanti; Angele Cucci; Andrea Veltri; Paolo Avagnina; Andrea Calvo; Adriano Chio'; Luca Durelli; Marinella Clerico
Journal:  J Neurol       Date:  2015-09-26       Impact factor: 4.849

Review 8.  Pathophysiology and Treatment of Non-motor Dysfunction in Amyotrophic Lateral Sclerosis.

Authors:  Colin J Mahoney; Rebekah M Ahmed; William Huynh; Sicong Tu; Jonathan D Rohrer; Richard S Bedlack; Orla Hardiman; Matthew C Kiernan
Journal:  CNS Drugs       Date:  2021-05-15       Impact factor: 5.749

9.  Amyotrophic Lateral Sclerosis: Integrated care provides the best quality of life.

Authors:  Jonathan R Brent; Senda Ajroud-Driss
Journal:  Pract Neurol (Fort Wash Pa)       Date:  2019 Jul-Aug

10.  Botulinum Toxin A for Sialorrhoea Associated with Neurological Disorders: Evaluation of the Relationship between Effect of Treatment and the Number of Glands Treated.

Authors:  Domenico A Restivo; Mariangela Panebianco; Antonino Casabona; Sara Lanza; Rosario Marchese-Ragona; Francesco Patti; Stefano Masiero; Antonio Biondi; Angelo Quartarone
Journal:  Toxins (Basel)       Date:  2018-01-27       Impact factor: 4.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.